Company Overview

Gilead Sciences, Inc. is a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines for life‑threatening diseases. The company operates primarily within the biotechnology and pharmaceutical industries, with a strong emphasis on antiviral therapies, oncology, and inflammatory diseases. Its business is driven by proprietary research, clinical development, regulatory approval, and global commercialization of prescription medicines.

Gilead is best known for its leadership in HIV therapeutics, where it has established durable market positions through combination antiviral regimens, as well as for its historical role in transforming the treatment of viral hepatitis. Over time, the company has diversified into oncology and cell therapy, most notably through acquisitions. Founded in 1987, Gilead evolved from a research‑focused biotechnology firm into a large‑scale commercial pharmaceutical company through internal R&D and strategic acquisitions, expanding both its therapeutic scope and global reach.

Business Operations

Gilead generates revenue primarily through the sale of branded prescription medicines across several therapeutic areas. Its core business segments include HIV, Oncology, Liver Diseases, and Inflammation and Respiratory Diseases, with the HIV franchise historically representing the largest share of revenue. Products are marketed directly in major markets and through partners or distributors in certain international territories.

The company operates globally with commercial, manufacturing, and research capabilities in multiple regions. A significant component of its oncology operations is conducted through Kite Pharma, a wholly owned subsidiary focused on cell therapy, particularly CAR‑T treatments. Gilead controls a portfolio of intellectual property, manufacturing facilities, and clinical development programs, and it engages in collaborations and licensing agreements to support drug development and geographic expansion.

Strategic Position & Investments

Gilead’s strategy centers on sustaining leadership in HIV, expanding its oncology portfolio, and advancing novel therapies in inflammation and virology. Growth initiatives include lifecycle management of existing products, advancement of late‑stage clinical programs, and selective business development to strengthen its pipeline. The company has emphasized scientific innovation combined with disciplined capital allocation.

Major strategic investments include the acquisition of Kite Pharma, which established Gilead’s presence in cell therapy, and Immunomedics, which significantly expanded its oncology franchise. Gilead continues to invest in emerging technologies such as next‑generation antiviral agents, immuno‑oncology approaches, and cell‑based therapies, while maintaining a portfolio of minority investments and partnerships aligned with its therapeutic focus areas.

Geographic Footprint

Gilead is headquartered in North America, with its principal executive offices in Foster City, California. The company has a significant commercial presence across North America, Europe, and Asia‑Pacific, and sells products in numerous countries worldwide. Manufacturing and research activities are distributed across multiple regions to support global supply and development needs.

International operations play a critical role in revenue generation, particularly in Europe and select Asia‑Pacific markets. Gilead also participates in access and licensing programs that extend the reach of its medicines into emerging markets, reinforcing its global operational and public health footprint.

Leadership & Governance

Gilead is led by an experienced executive team with backgrounds in pharmaceuticals, biotechnology, and global operations. The leadership emphasizes a strategy focused on scientific innovation, disciplined investment, and long‑term value creation, while maintaining corporate governance aligned with public company standards and regulatory requirements.

Key executives include:

• Daniel O’Day – Chairman and Chief Executive Officer
• Andrew Dickinson – Chief Financial Officer
• Johanna Mercier – Chief Commercial Officer
• Merdad Parsey – Chief Medical Officer
• Deborah Waterhouse – Chief Executive Officer, Kite Pharma

The board and management team oversee strategic direction, risk management, and capital allocation, with a stated focus on advancing transformative medicines and maintaining ethical and compliance‑driven operations.